ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans

This study has been completed.

Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00017732
  Purpose

RSH/Smith-Lemli-Opitz syndrome (SLOS) is one that causes mental retardation. It is common in the Caucasian population but rare in African American and African black populations. It has been shown that SLOS is caused by a specific defect in DHCR7, an enzyme used in cholesterol metabolism. Studies have already been done to determine the frequency of the SLOS-causing mutations in various geographic Caucasian populations. This study will investigate the frequency of the DHCR7 mutations in the African American population. If the frequency observed suggests that SLOS cases are not being identified in this ethnic group, the study will provide the rationale for future studies to identify these patients.

The sample size will be 1,600. The study population will consist of archived biological specimens in the form of newborn screening blood spots from two newborn screening centers, one in Maryland and one in Pennsylvania. Subjects will be of African American ethnicity, including blacks of African, Caribbean, and Central American descent.

Genomic DNA will be extracted from blood spots and screened for the six common SLOS mutations. If SLOS syndrome is found, followup will be attempted for the Maryland samples (the Pennsylvania samples will be totally anonymous).


Condition
Smith-Lemli-Opitz Syndrome

Genetics Home Reference related topics:   cholesteryl ester storage disease    Farber lipogranulomatosis    long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency    mitochondrial trifunctional protein deficiency    primary carnitine deficiency    Smith-Lemli-Opitz syndrome   

MedlinePlus related topics:   Cholesterol   

Drug Information available for:   Cholest-5-en-3-ol (3beta)-   

U.S. FDA Resources

Study Type:   Observational
Official Title:   Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:   2000
Study Start Date:   June 2001
Estimated Study Completion Date:   March 2003

Detailed Description:

RSH/Smith-Lemli-Opitz syndrome (SLOS) is a multiple congenital anomaly/mental retardation syndrome caused by inborn error of cholesterol metabolism (Tint et al. 1994; Opitz 1999; Kelley 2000). Recent studies have shown SLOS to be one of the most common inherited metabolic defects in the Caucasian population. SLOS is believed to be rare in people of Chinese, Japanese, Indian, and Korean origin as well as in the African American and African Black population (Tsukahara et al. 1998; Yu et al 2000a; Witsch-Baumgartner et al. 2000; Witsch-Baumgartner et al. 2001, Battaile et al. 2001). The frequency spectra of DHCR7 mutations have been established for American Caucasians (Yu et al. 2000b, Battaile et al. 2001), mixed American Caucasian collection of patients (Witsch-Baumgartner et al 2000), for European ethnic groups from Poland, German/Austria, Great Britain (Witsch-Baumgartner et al. 2001) and from Italy (De Brasi et al. 1999). In these Caucasian populations, the most common mutations (IVS8-1G>C, W151X, V326L, R352W, R404C and T93M) account for 60% of SLOS mutant alleles. These suggest that frequent SLOS-causing mutations have different geographic origins and histories. This project will investigate the frequency gradient of DHCR7 mutations in the African American population.

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

INCLUSION CRITERIA:

These will be newborn screening blood spots from African American babies. Samples from Blacks of African, Caribbean and Central American descent will be included. The classification of the infants will be based on the maternal identification as Black or African American by blood spot submission card.

EXCLUSION CRITERIA:

Newborn screening blood spots from non-African American or non-Black babies.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00017732

Locations
United States, Maryland
National Institute of Child Health and Human Development (NICHD)    
      Bethesda, Maryland, United States, 20892

Sponsors and Collaborators
  More Information


Publications:

Study ID Numbers:   010191, 01-CH-0191
First Received:   June 8, 2001
Last Updated:   March 3, 2008
ClinicalTrials.gov Identifier:   NCT00017732
Health Authority:   United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Malformations  
Ethnicity  
Mutations  
Cholesterol  
Metabolism
Smith-Lemli-Opitz Syndrome
SLOS
Cholesterol Metabolism

Study placed in the following topic categories:
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Opitz syndrome
Metabolic Diseases
Genetic Diseases, Inborn
Abnormalities, Multiple
Metabolic disorder
Smith-Lemli-Opitz Syndrome
Congenital Abnormalities
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Pathologic Processes
Disease
Syndrome
Steroid Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers